HLA-DRA and neoplasm: In total, five populations were designated tumour clusters, which had various features: (TumourC0) CD74 and APOD; (TumourC1) IF16, JUN and HSPA1A; (TumourC2) S100B and SCRG1; (TumourC3) NEAT1 and MALAT1; and (TumourC4) WFDC2 and RNASE1 (HLA‐DRA, CD68, CD3D, CD3E).